Filtered By:
Source: Current Pharmaceutical Design
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 176 results found since Jan 2013.
MicroRNAs as Big Regulators of Neural Stem/Progenitor Cell Proliferation, Differentiation and Migration: A Potential Treatment for Stroke.
CONCLUSION: Promising but full of hurdles, miRNAs have been confirmed to play a critical role in regulating NSPCs. Clinical potentials of miRNAs are huge in treating stroke patients receiving NSPCs-based therapy, which can be used as biomarkers for the diagnosis and prognosis, and as targets for controlling the proliferation, differentiation and migration of NSPCs.
PMID: 28245761 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 27, 2017 Category: Drugs & Pharmacology Authors: Zhang Q, Zhang K, Zhang C, Ge H, Yin Y, Feng H, Hu R Tags: Curr Pharm Des Source Type: research
Exosomes in Ischemic Stroke.
Abstract
Ischemic stroke, a leading cause of mortality, results in severe neurological outcomes in the patients. Effective stroke therapies may significantly decrease the extent of injury. For this purpose, novel and efficient drug delivery strategies need to be developed. Among a myriad of therapeutic and drug delivery techniques, exosomes have shown promising results in ischemic stroke either by their intrinsic therapeutic characteristics, which can result in angiogenesis and neurogenesis or by acting as competent, biocompatible drug delivery vehicles to transport neurotherapeutic agents into the brain. In this ...
Source: Current Pharmaceutical Design - June 13, 2020 Category: Drugs & Pharmacology Authors: Nozohouri S, Vaidya B, Abbruscato TJ Tags: Curr Pharm Des Source Type: research
Lipid metabolism genes in stroke pathogenesis: The Atherosclerosis.
Abstract
Stroke is the second leading cause of death and a major cause of disability worldwide. Both modifiable and non-modifiable risk factors can affect the occurrence of ischemic stroke at varying degrees. Among them, atherosclerosis has been well recognized as one of the main culprits for the rising incidence of stroke-related mortality. Hence, the current review aimed to summarize the prominent role of lipid metabolism genes such as PCSK9, ApoB, ApoA5, ApoC3, ApoE and ABCA1 in mediating ischemic stroke occurrence.
PMID: 32534558 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 13, 2020 Category: Drugs & Pharmacology Authors: Chow YL, Teh LK, Chih LH, Lim LF, Yee CC, Wei LK Tags: Curr Pharm Des Source Type: research
Molecular hydrogen application in stroke: bench to bedside.
Abstract
Stroke is a major cause of mortality and morbidity worldwide. Effective treatments are limited. Molecular hydrogen is emerging as a novel medical gas with therapeutic potential for various neurological diseases, including stroke. We reviewed the experimental and clinical findings of the effects of molecular hydrogen therapy in stroke patients and models. The underlying neuroprotective mechanisms aganist stroke pathology were also discussed.
PMID: 32940172 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - September 16, 2020 Category: Drugs & Pharmacology Authors: Huang L, Lenahan C, Boling W, Tang J, Zhang JH Tags: Curr Pharm Des Source Type: research
Visit-to-visit blood pressure variability and classes of antihypertensive agents; associations with artery remodeling and the risk of stroke.
Abstract
Recent studies have shown that visit-to-visit blood pressure (BP) variability was emerging as an independent risk factor for stroke. Although the mechanism is not fully understood, artery remodeling would be closely associated with the relationship between visit-to-visit BP variability and stroke. In addition, the class of antihypertensive agents is suggested to be an important determinant of visit-to-visit BP variability. This review article summarizes the recent literature on these topics. In the elderly hypertensives, strict BP control using calcium channel blockade would play a crucial role to prevent...
Source: Current Pharmaceutical Design - November 12, 2015 Category: Drugs & Pharmacology Authors: Nagai M, Dote K, Kato M, Sasaki S, Oda N, Kagawa E, Nakano Y, Yamane A, Kubo Y, Higashihara T, Miyauchi S, Harada W Tags: Curr Pharm Des Source Type: research
Stroke and Neuroinflamation: Role of Sexual Hormones.
Abstract
Inflammatory response in the nervous system, called neuroinflammation, is a common process of several neurodegenerative diseases and brain disorders. To understand the underlying mechanism of this brain response to damage would be interesting to identify new common therapy targets to neurodegenerative processes. Ischemic stroke has an important socioeconomic impact being the second cause of mortality and the first cause of long-term disability in the world. Until now, there is not any pharmacological treatment to reduce the brain damage induced. In this review, we will expose recent evidences about neuroi...
Source: Current Pharmaceutical Design - March 15, 2016 Category: Drugs & Pharmacology Authors: Perez-Alvarez MJ, Wandosell F Tags: Curr Pharm Des Source Type: research
Heme oxygenase-1: clinical relevance in ischemic stroke.
Abstract
Stroke is the second-leading cause of death and a leading cause of serious long-term disability worldwide, with an icreasing global burden due to the growing and aging population. However, strict eligibility criteria for current treatment opportunities make novel therapeutic apporaches desirable. Oxidative stress plays a pivotal role during cerebral ischemia, eventually leading to neuronal injury and cell death. The significant correlation between redox imbalance and ischemic stroke has led to various treatment strategies targeting the endogenous antioxidant system in order to ameliorate the adverse progn...
Source: Current Pharmaceutical Design - July 16, 2018 Category: Drugs & Pharmacology Authors: Bereczki D, Balla J, Bereczki D Tags: Curr Pharm Des Source Type: research
Risk factors of recurrent ischemic events after acute noncardiogenic ischemic stroke.
CONCLUSION: MPV, ADP% and MA were risk factors of recurrent ischemic events after acute noncardiogenic ischemic stroke. Urgent assessment and individual drug therapy should be offered to these patients as soon as possible.
PMID: 31663472 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 27, 2019 Category: Drugs & Pharmacology Authors: Zhang L, Li X, Wang D, Lv H, Si X, Li X, Sun Y, Wang D, Chen K, Kang X, Lou X, Zhang G, Ma N Tags: Curr Pharm Des Source Type: research
Antithrombotic therapy in patients with recent stroke and atrial fibrillation.
Abstract
Atrial fibrillation (AF) is a common arrhythmia which carries a significant risk of stroke. Secondary prevention, in particular in the acute phase of stroke with anti-thrombotic therapy has not been validated. The aim of this review is to evaluate the available evidence on the use of antithrombotic therapy in patients with recent stroke who have AF, and suggest a treatment algorithm for the various time points, taking into account both the bleeding and thrombosis risks posed at each stage.
PMID: 32264805 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - April 6, 2020 Category: Drugs & Pharmacology Authors: Saberwal B, Ioannou A, Lim WY, Beirne AM, Chow AW, Tousoulis D, Ahsan S, Papageorgiou N Tags: Curr Pharm Des Source Type: research
Endothelial Dysfunction and Inflammation in Ischemic Stroke Pathogenesis.
Abstract
Stroke is an heterogenous disease andwithin the broad large category of brain ischemia and its subtypesvary dramatically in cause. Endothelium is able to regulate the vascular homeostasis by modulating processes of vascular dilation and constriction by producing and secreting cytokines and chemical mediators and inflammation represent one of the most important factors that contribute to alteration in vessel structure and function by a dysregulation of this fine balance. Endothelial dysfunction represents a basic determinant of the vascular damage which can be identified in all different clinical subtypes ...
Source: Current Pharmaceutical Design - April 16, 2020 Category: Drugs & Pharmacology Authors: Tuttolomondo A, Daidone M, Pinto A Tags: Curr Pharm Des Source Type: research
Role of Inflammasomes in Atherosclerosis and Stroke Pathogenesis.
Abstract
Inflammation is a devastating outcome of cerebrovascular diseases (CVD), namely stroke and atherosclerosis. Numerous studies over the decade have shown that inflammasomes play a role in mediating inflammatory reactions post cellular injury occurring after stroke or a rupture of an atherosclerotic plaque. In view of this, targeting these inflammatory pathways using different pharmacological therapies may improve outcomes in patients with CVD. Here we review the mechanisms by which inflammasomes drive the pathogenesis of stroke and atherosclerosis. Also discussed here are the possible treatment strategies a...
Source: Current Pharmaceutical Design - April 25, 2020 Category: Drugs & Pharmacology Authors: Sarmah D, Datta A, Raut S, Sarkar A, Shah B, Bohra M, Singh U, Jagtap P, Baidya F, Kalia K, Wang X, Dave KR, Yavagal DR, Bhattacharya P Tags: Curr Pharm Des Source Type: research
Pathophysiology of ischemic stroke: role of oxidative stress.
Abstract
Stroke is the second leading cause of mortality and the major cause of adult physical disability worldwide. The current available treatment to recanalize the blood flow in acute ischemic stroke is intravenous administration of tissue plasminogen activator (t-PA) and endovascular treatment. Nevertheless, those treatments have the disadvantage that reperfusion leads to a highly harmful reactive oxygen species (ROS) production, generating oxidative stress (OS), which is responsible for most of the ischemia-reperfusion injury and thus causing brain tissue damage. Also, OS can lead brain cells to apoptosis, au...
Source: Current Pharmaceutical Design - July 7, 2020 Category: Drugs & Pharmacology Authors: Orellana-Urzúa S, Rojas I, Líbano L, Rodrigo R Tags: Curr Pharm Des Source Type: research
Current Perspectives regarding Stem Cell-based Therapy for Ischemic Stroke.
Abstract
Stroke is a leading cause of death and disability worldwide. Conventional treatment has a limitation of very narrow therapeutic time window and its devastating nature necessitate a novel regenerative approach. Transplanted stem cells resulted in functional recovery through multiple mechanisms including neuroprotection, neurogenesis, angiogenesis, immunomodulation, and anti-inflammatory effects. Despite the promising features shown in experimental studies, results from clinical trials are inconclusive from the perspective of efficacy. The present review presents a synopsis of stem cell research on ischemic...
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Park YS, Lee JW, Kwon HB, Kwak KA Tags: Curr Pharm Des Source Type: research
Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future.
CONCLUSION: Thrombolytic therapy is sometimes accompanied by harmful hemorrhagic insults; accordingly, a window of time wherein therapy can safely be performed has been established for this approach. Several basic and clinical studies are ongoing to develop next-generation thrombolytic drugs to expand the time window.
PMID: 30892155 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - March 17, 2019 Category: Drugs & Pharmacology Authors: Shibata K, Hashimoto T, Miyazaki T, Miyazaki A, Nobe K Tags: Curr Pharm Des Source Type: research
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
CONCLUSION: The current results demonstrated KDM4A inhibition improves functional recovery in ischemic stroke by repressing NF-κB activation and subsequent neuroinflammation.
PMID: 33402077 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 5, 2021 Category: Drugs & Pharmacology Authors: Liu Y, Zhao L, Zhang J, Lv L, Han K, Huang C, Xu Z Tags: Curr Pharm Des Source Type: research
